The regulatory role of TGF-β in the CD8+ effector function is best evidenced by a variety of in vivo models of tumor, infection, and inflammation in mice in which TGF-β signaling is altered by either genetic manipulation or inhibition with antibodies or inhibitors. The gene discussed is CD8A; the disease is neoplasm.